Retrospective, Observationnal Study to Investigate Procedural Analgesia Delivered to Patients With Lacerations, Abrasions, Burns and Leg Ulcers.
APPABU
Retrospective and Observational Category 3 Study to Investigate Procedural Analgesia Delivered to Patients With Skin Injury, Aiming to Describe and Quantify Therapeutic Pain Control Procedures Addressing Skin Lacerations, Abrasions, Burns and Leg Ulcers.
1 other identifier
observational
240
1 country
1
Brief Summary
The main part of the study is a retrospective analysis of 200 reports concerning patients with skin wounds and injuries :
- 50 consecutive patient reports dealing with skin lacerations
- 50 consecutive patient reports dealing with skin abrasions
- 50 consecutive patient reports dealing with skin burns
- 50 consecutive patient reports dealing with leg ulcers The study comprises a complementary prospective segment, consisting of data collection from patients and from care delivery personnel, threw short interviews, in order to assess the validity of the retrospective recording on reports.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 11, 2024
CompletedFirst Submitted
Initial submission to the registry
November 6, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 15, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
July 15, 2025
CompletedFirst Posted
Study publicly available on registry
January 20, 2026
CompletedJanuary 20, 2026
January 1, 2026
7 months
November 6, 2024
January 9, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Pain level
Pain level ≤ 3/10 (light or no pain) on a 10-point pain scale throughout the interval starting 30 minutes after treatment initiation and ending.
Up to 30 minutes
Study Arms (4)
Procedural analgesia delivered to patients with dermabrasion
Hospital reports of patients who were treated in the emergency deparment for skin abrasion
Procedural analgesia delivered to patients with skin burn
Hospital reports of patients who were treated in the emergency department for skin burn
Procedural analgesia delivered to patients with leg ulcer
Hospital reports of patients who were treated in the vascular department for leg ulcer
Procedural analgesia delivered to patients with skin lacerations
Hospital reports of patients who were treated in the emergency deparment for skin lacerations
Eligibility Criteria
Adult patients with skin injuries (consulting emergency departments for skin laceration abrasion or burn, consulting vascular unit for patients with leg ulcer).
You may qualify if:
- Main retrospective study: Adult patient with skin injury (laceration, abrasion, burn or skin ulcer) whose medical report is available.
- Additionnal prospective interview: Adult patient with skin injury (laceration, abrasion, burn or skin ulcer) who consents to the 10-minute interview.
You may not qualify if:
- Main retrospective study: medical report incomplete. Additionnal prospective interview: Not french speaking.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hospital Versailles
Le Chesnay, 78150, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Investigator Coordonnator
Study Record Dates
First Submitted
November 6, 2024
First Posted
January 20, 2026
Study Start
June 11, 2024
Primary Completion
January 15, 2025
Study Completion
July 15, 2025
Last Updated
January 20, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will not share
Clinical, treatment and logistical data will be anonymously be recorded (ther will be no mention of age, gender, name, letters or numbers to identify participants): IPD will not be collected and therefore not shared.